Fresenius Medical Care AG & Co. KGaA (“the Company”) (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world’s largest provider of Dialysis Products and Services, today announced that it intends to sell approximately US$ 500 million senior unsecured notes. The notes will be offered mainly to US institutional investors. Proceeds from the offering will be used to reduce indebtedness under the Company’s senior secured bank credit facility and other, short-term debt, and for general corporate purposes.
The proposed offering will not be registered under the Securities Act of 1933, but will be offered in the United States pursuant to an exemption from registra-tion under Rule 144A as well as outside the United States under Regulation S. The Company expects completion of the offering at the beginning of July 2007.
The proposed offering will not be registered under the Securities Act of 1933, but will be offered in the United States pursuant to an exemption from registra-tion under Rule 144A as well as outside the United States under Regulation S. The Company expects completion of the offering at the beginning of July 2007.
